Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$2.04+0.5%$3.57$1.86▼$14.64$6.32M1.7388,871 shs80,136 shsPREPrenetics Global$18.74-3.5%$19.03$7.18▼$23.63$316.22M0.26250,650 shs149,200 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-5.56%-28.67%-62.91%-82.59%PREPrenetics Global0.00%+2.46%-5.11%+2.24%+117.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$2.04+0.5%$3.57$1.86▼$14.64$6.32M1.7388,871 shs80,136 shsPREPrenetics Global$18.74-3.5%$19.03$7.18▼$23.63$316.22M0.26250,650 shs149,200 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-5.56%-28.67%-62.91%-82.59%PREPrenetics Global0.00%+2.46%-5.11%+2.24%+117.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$13.00537.25% UpsidePREPrenetics Global 2.60Moderate Buy$34.2582.76% UpsideCurrent Analyst Ratings BreakdownLatest PRE and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026PREPrenetics Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026PREPrenetics Global BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.006/16/2026PREPrenetics Global BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/APREPrenetics Global$92.39M3.42N/AN/A$9.27 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)PREPrenetics Global-$37.71M-$4.58N/AN/AN/A-62.45%-20.33%-15.42%9/11/2026 (Estimated)Latest PRE and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026CVKDCadrenal Therapeutics-$1.42N/AN/AN/AN/AN/A6/10/2026Q1 2026 PreliminaryPREPrenetics Global-$0.49-$0.56-$0.07-$1.36$36.00 million$35.95 million5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A2.682.68PREPrenetics GlobalN/A5.154.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics43.10 million2.29 millionNot OptionablePREPrenetics Global116.87 million15.56 millionNot OptionablePRE and CVKD HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Prenetics Global (NASDAQ:PRE) to SellJuly 25 at 1:30 AM | americanbankingnews.comPrenetics Global (NASDAQ:PRE) Lowered to "Sell" Rating by Wall Street ZenJuly 25 at 1:29 AM | marketbeat.comPrenetics Global: Path To Profitability On Course With Financing DealJuly 24 at 12:48 PM | seekingalpha.comTESLA AND ALPHABET SHARES SLUMP IN PRE-MARKET TRADINGJuly 23 at 7:00 AM | youtube.comYSidoti Estimates Prenetics Global's Q3 Earnings (NASDAQ:PRE)July 19, 2026 | americanbankingnews.comPrenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook RisesJuly 17, 2026 | theglobeandmail.comPRE Continues to Exceed Expectations and Receive Preferential FinancingJuly 17, 2026 | msn.comPrenetics CEO on securing $1 billion funding to fuel subsidiary IM8's growthJuly 17, 2026 | msn.comQ3 Earnings Forecast for Prenetics Global Issued By SidotiJuly 17, 2026 | marketbeat.comPrenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 17, 2026 | americanbankingnews.comQ1 Earnings Estimate for Prenetics Global Issued By SidotiJuly 16, 2026 | marketbeat.comPrenetics Global (NASDAQ:PRE) Given New $40.00 Price Target at BenchmarkJuly 16, 2026 | americanbankingnews.comPrenetics Global (NASDAQ:PRE) Price Target Raised to $40.00July 15, 2026 | marketbeat.comPrenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)July 14, 2026 | markets.businessinsider.comPrenetics Raises $1 Billion Growth Financing from General Catalyst for IM8 and Lifts 2026 Revenue Guidance to $210 Million-$220 MillionJuly 14, 2026 | quiverquant.comQPrenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF)July 14, 2026 | globenewswire.comPrenetics Global Limited (NASDAQ:PRE) Given Average Rating of "Moderate Buy" by BrokeragesJuly 12, 2026 | marketbeat.comPrenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market GrowthJune 25, 2026 | insidermonkey.comPrenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market GrowthJune 25, 2026 | finance.yahoo.comCEO chat with Danny Yeung, co-founder and CEO of Prenetics GlobalJune 23, 2026 | msn.comPrenetics Posts Record 2025 Results as IM8 Hits $120 Million ARR and Drives Strategic RefocusJune 15, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRE and CVKD Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$2.04 +0.01 (+0.49%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.00 -0.04 (-2.21%) As of 07/24/2026 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Prenetics Global NASDAQ:PRE$18.74 -0.68 (-3.50%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.14 +0.40 (+2.13%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
